Ibrucon
Ibrucon is Ibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor. It is indicated for CLL, mantle cell lymphoma, Waldenstrom macroglobulinemia, and other B-cell malignancies and works by blocking B-cell receptor signaling and reducing malignant cell survival.
Features
| Product Name | Ibrucon |
| Generic Name | Ibrutinib |
| Formulation | Capsule |
| Available Pack Size | 4X6's |
| Available Strength | 140MG |